Pharmaceuticals and Biotechnology Litigation
In this Jan-Mar 2023 issue of Corporate Disputes e-magazine, Sean Sheridan, along with other industry professionals, discusses significant developments shaping...
CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.
Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.
Engagements
- 01Evaluation of an asthma medication with once-a-day dosingIn a Hatch-Waxman litigation involving a drug for asthma, CRA was asked to assess commercial success and its nexus to the patent. In this case, the patent...View engagement
- 02Assessment of irreparable harm for an osteoporosis treatmentFollowing a district court finding of invalidity and/or non-infringement and plaintiff’s stated intention to appeal, CRA was asked to assess whether branded...View engagement
- 03At risk generic entry and impact of formulary statusIn a Hatch-Waxman litigation, a first-to-file generic manufacturer asked CRA to assess changes in formulary status that would result from the at-risk entry and...View engagement